Ipilimumab (Yervoy) — CPB 0815 | AETNA Coverage Update

Aetna modified CPB 0815 for ipilimumab (Yervoy), effective October 18, 2025. Here's what billing teams need to know before submitting claims under J9228.

Aetna, a CVS Health company, updated its ipilimumab coverage policy under CPB 0815 Aetna system, expanding medically necessary indications across a wide range of oncology diagnoses. This update adds and refines criteria for tumor mutational burden-high (TMB-H) cancers, MSI-H/dMMR tumors, and several rarer malignancies. If your practice bills J9228 (injection, ipilimumab, 1 mg) alongside J9299 (nivolumab) or J9271 (pembrolizumab), this policy touches every one of those claims. The change affects oncology billing across multiple ICD-10 categories—261 diagnosis codes in total.

Quick-Reference Table

Aetna Ipilimumab Coverage Criteria and Medical Necessity Requirements 2025

Precertification is required for every J9228 claim under this coverage policy. Call (866) 752-7021 or fax (888) 267-3277. No exceptions.

Aetna's medical necessity criteria under CPB 0815 now cover ipilimumab across a broad set of solid tumor diagnoses. The common thread: most approvals require ipilimumab in combination with nivolumab (J9299), and most require specific molecular tumor testing to establish eligibility. That testing generates its own codes—CPT 81301 for microsatellite instability analysis and CPT 88342/+88341 for immunohistochemistry—so your documentation and billing need to move together.

The policy organizes approval criteria by indication. For each one, Aetna sets specific rules around line of therapy, tumor biomarker status, and combination regimen structure. Several indications require TMB-H status (≥10 mutations/megabase), which must be documented from a validated assay. Others require MSI-H or dMMR confirmation. If the biomarker documentation isn't in the chart, prior authorization won't move.

Site of care is also in play here. Aetna's Site of Care Utilization Management Policy applies to ipilimumab infusions. That affects where your team can bill 96413 (chemotherapy administration, IV infusion, up to 1 hour) and 96415 (each additional hour). If you're billing those codes in a setting Aetna doesn't consider appropriate for specialty drug infusions, expect a claim denial.

Aetna Ipilimumab Exclusions and Non-Covered Indications

Bevacizumab (J9035) and its biosimilar bevacizumab-awwb (Q5107) are explicitly listed as experimental and investigational when used in combination with ipilimumab. Don't bill those combinations expecting coverage under CPB 0815.

Stomach cancer (ICD-10 C16.0–C16.9) is covered only when ipilimumab is used with nivolumab. Single-agent ipilimumab for gastric malignancies is not covered under this policy.

Several combination regimens appear in the policy as "other HCPCS codes related to the CPB" rather than as covered codes. Irinotecan (J9206) and oxaliplatin (J9263) fall into that category. Listing them on the same claim as J9228 won't generate automatic reimbursement—those drugs need their own coverage support separate from this policy.

Coverage Indications at a Glance

Aetna Ipilimumab Billing Guidelines and Action Items 2025

1. Verify precertification is in place before October 18, 2025.
Every J9228 claim requires precertification. If you have active patients on ipilimumab regimens, confirm existing authorizations cover the updated indication criteria. Don't assume a prior auth granted under the old policy carries forward automatically.

2. Confirm biomarker documentation is in the chart before billing.
Aetna will deny claims where the medical necessity criteria require TMB-H, MSI-H, or dMMR status but the documentation doesn't reflect a validated assay result. CPT 81301 (MSI analysis) and CPT 88342/+88341 (immunohistochemistry) generate billable encounters that also serve as supporting documentation. Make sure those results are tied to the chart before the J9228 claim goes out.

3. Check BRAF status for melanoma claims.
CPT 81210 (BRAF gene analysis) appears in this policy's code set for melanoma. If your oncology team uses BRAF status in treatment decisions, document that in the precertification record. It won't hurt—and missing it might.

4. Audit combination regimen billing for nivolumab and pembrolizumab.
Most covered indications require ipilimumab in combination with nivolumab (J9299). A smaller set uses pembrolizumab (J9271). Bill both drugs on the same date of service when the regimen calls for it. Billing J9228 alone on a date where the protocol calls for combination therapy creates a documentation mismatch that triggers review.

5. Confirm site of care compliance before billing 96413 and 96415.
Aetna's Site of Care policy applies here. If you're billing ipilimumab infusions in a setting that doesn't meet Aetna's site-of-service criteria, the claim will be denied—even if the indication is covered. Check your infusion center's designation against Aetna's utilization management policy before the effective date of October 18, 2025.

6. Do not bill bevacizumab (J9035 or Q5107) in combination with ipilimumab.
Those combinations are explicitly experimental under CPB 0815. You will not get reimbursement, and repeated billing on experimental indications creates audit risk.

7. For complex mixed-indication patients, loop in your compliance officer.
If you have patients with overlapping diagnoses—say, a GI malignancy with hepatic involvement spanning multiple ICD-10 categories—get a compliance officer or billing consultant to review which indication governs the claim before you submit. The policy is detailed, and the wrong ICD-10 selection on a claim this high-value creates serious exposure.

CPT, HCPCS, and ICD-10 Codes for Ipilimumab Under CPB 0815

HCPCS Codes — Covered When Selection Criteria Are Met

HCPCS Codes — Related to CPB (Not Automatically Covered)

CPT Codes — Related to CPB

Key ICD-10-CM Diagnosis Codes

Note: The full policy lists 261 ICD-10-CM codes. The table above reflects the code ranges explicitly provided in the policy data. Review the complete CPB 0815 document at app.payerpolicy.org/p/aetna/0815 for the full diagnosis code list before finalizing your charge capture.